Megan Hollasch

Articles

Dose-Optimized Regorafenib Leads to Improved Survival in mCRC

September 16th 2022

Dose optimization of regorafenib led to improved survival outcomes compared with best supportive care of fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil in patients with relapsed/refractory metastatic colorectal cancer.

Daratumumab Compliance Rates in Multiple Myeloma Maintained in Real-World Analysis

September 2nd 2022

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Benefit of Daratumumab Plus RVd Is Maintained Without Additional Toxicities Among Black Patients With NDMM

August 31st 2022

A subgroup analysis of the phase 2 GRIFFIN trial confirmed that Black patients with newly diagnosed multiple myeloma elicited a benefit from treatment with daratumumab added to lenalidomide, bortezomib, and dexamethasone without additional toxicities.

Trastuzumab Deruxtecan Approval for HER2-Low Breast Cancer Sparks Bright Future for ADCs

August 29th 2022

Shanu Modi, MD, discusses the significance of the approval of trastuzumab deruxtecan for patients with HER2-low breast cancer.

Promising Data for Treatment of Myelofibrosis Emerges With Pelabresib and Ruxolitinib Combination

August 22nd 2022

John Mascarenhas, MD, discussed the effect of the data from MANIFEST on the treatment landscape and the future of adding active agents to ruxolitinib for treatment of myelofibrosis.

Trastuzumab Deruxtecan Expands the Targeted Landscape for HER2-mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

Anbalcabtagene Autoleucel Shows Promise in Relapsed/Refractory LBCL

August 17th 2022

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease

August 15th 2022

Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.

Retrospective Analysis Highlights Disparities in Germline Testing in Prostate Cancer

August 2nd 2022

Carrie Horton, MS, CGC, discusses how the findings from a retrospective analysis of germline testing rates among racially diverse groups of men with prostate cancer will guide future research and influence the steps community oncologists can take to increase testing rates.

CRESTONE Data Signal Positive Start to Treat Rare NRG1 Fusions in Solid Tumors

August 1st 2022

Results of the phase 2 CRESTONE study have demonstrated the tolerable safety profile and efficacy of seribantumab for the treatment adult patients with metastatic solid or locally advanced tumors harboring the rare NRG1 fusions.

Brahmer Discusses Influence of 5-Year Nivolumab and Ipilimumab OS Data in Metastatic NSCLC

July 22nd 2022

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.